ARTICLES BY TYLER MENICHIELLO
-
The Industry’s Positive Outlook For ADCs In 20242/26/2024
Check out the results of DeciBio's Antibody-Drug Conjugates 2024 Industry Survey, which predict another bullish year for the growing modality.
-
2023 ADC Roundup: A Year Of Collaboration And Licensing Deals1/3/2024
Despite the continuation of a poor funding climate in biotech, 2023 was a big year for antibody-drug conjugates (ADCs).
-
Considerations For Licensing Platforms From Universities6/16/2023
Even the best platforms and technologies don’t come out of universities IND-ready. Just ask Coeptis Therapeutics, which recently licensed the novel CAR-T platform, SNAP-CAR, from the University of Pittsburgh. Coeptis’ Dave Mehalick, and Dan Yerace discuss the licensing agreement and the growing pains to expect when preparing a new platform for an IND.
This website uses cookies to ensure you get the best experience on our website. Learn more